Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-17Clinical Trial Update: Mastication, Cognition, and Nutritional Status in Multiple Sclerosis
A clinical trial at Ondokuz Mayıs University is investigating how mastication relates to cognition and nutritional status in people with Mul…
-
CLINICAL_TRIALS research · 2026-02-13Clinical Trial Update: BrainAgeMS - a Comparative Study of Brain Aging in Healthy and Patients With Multiple Sclerosis
A clinical trial comparing brain aging in healthy individuals and patients with Multiple Sclerosis is currently recruiting in Switzerland (I…
-
FDA approval · 2026-02-12FDA Approved: GLATOPA — Supplemental Application (Sandoz Inc)
The FDA approved Sandoz's supplemental application for GLATOPA (glatiramer acetate), a generic injectable for multiple sclerosis.
-
FDA approval · 2026-02-12FDA Approved: GLATOPA — Supplemental Application (Sandoz Inc)
FDA approved GLATOPA, a generic glatiramer acetate product by Sandoz, via a supplemental application to an approved ANDA for use in multiple…
-
FDA label_change · 2026-02-11FDA Approved: AUBAGIO — Supplemental Application (Genzyme Corporation)
FDA approved a supplemental application for Aubagio (teriflunomide) filed by Genzyme Corporation, resulting in labeling updates for the drug…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases [EARLY_Phase 1]
This document reports an early-phase (Phase 1) clinical trial of QT-019C UCAR T-cell therapy targeting CD19 and BCMA in relapsed/refractory …
-
FDA approval · 2026-02-11FDA Approved: GLATIRAMER ACETATE — Original Application (AJENAT PHARMACEUTICALS LLC)
FDA approved a generic version of glatiramer acetate (AJENAT Pharmaceuticals LLC) under an original ANDA for the treatment of multiple scler…
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101
A long-term follow-up study for participants previously treated with KYV-101; recruitment is ongoing across multiple autoimmune diseases.
-
CLINICAL_TRIALS trial_result · 2026-02-11Clinical Trial Update: In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases [NA]
A completed clinical trial update reporting an in vitro study of interleukin-2 muteins on regulatory T cells in patients with autoimmune, al…
-
FDA approval · 2026-02-11FDA Approved: GLATIRAMER ACETATE — Original Application (AJENAT PHARMACEUTICALS LLC)
The FDA approved an original application for a generic glatiramer acetate product by AJENAT Pharmaceuticals LLC, enabling a generic treatmen…
-
CLINICAL_TRIALS research · 2026-02-11Clinical Trial Update: Effect of Sensory Integration Therapy on Gait Variability and Quality Of Life in Patients With Multiple Sclerosis [NA]
This clinical trial is evaluating the effect of sensory integration therapy on gait variability and quality of life in people with Multiple …
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) [Phase 1]
A Phase 1 study evaluating CC-97540 in relapsing and progressive forms of multiple sclerosis and refractory myasthenia gravis is currently r…
-
CLINICAL_TRIALS research · 2026-02-10Clinical Trial Update: Music-Augmented Rhythmic Gait Training in Multiple Sclerosis [NA]
This entry notes a clinical trial evaluating music-augmented rhythmic gait training for people with multiple sclerosis, and it is currently …
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Effects of Ublituximab on Motor Functions in Multiple Sclerosis [EARLY_Phase 1]
An early-phase 1 trial is evaluating the effects of ublituximab on motor function in relapsing-remitting multiple sclerosis and is currently…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: CorEvitas Multiple Sclerosis (MS) Registry
An update on CorEvitas's Multiple Sclerosis Registry, with enrollment currently by invitation.
-
CLINICAL_TRIALS trial_result · 2026-02-06Clinical Trial Update: Investigation of the Effect of the MIND Diet on Disease Symptoms in Patients With MS [NA]
This completed clinical trial evaluated the impact of the MIND Diet on disease-related symptoms in individuals with multiple sclerosis.
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: Influence of Therapeutic Failure on the Psychosocial Experience in Multiple Sclerosis
This clinical trial update outlines a study investigating how therapeutic failure impacts the psychosocial experience of individuals with mu…
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in France
A real-world French study evaluating quality of life in multiple sclerosis patients treated with ofatumumab.
-
CLINICAL_TRIALS research · 2026-02-06Clinical Trial Update: At Home Use of Stimulation Suits for Managing MS Symptoms [NA]
A clinical trial is recruiting to assess home-based stimulation suits for managing symptoms of multiple sclerosis, including spasticity and …
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis [Phase 3]
This document describes a Phase 3 pediatric trial comparing ozanimod to fingolimod in children and adolescents with relapsing-remitting mult…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis [Phase 4]
A Phase 4 clinical trial update for ublituximab addressing ocrelizumab wearing-off in people with multiple sclerosis; the study is not yet r…
-
CLINICAL_TRIALS trial_result · 2026-02-04Clinical Trial Update: Validity and Reliability of the 6-minute Walk Test Over a Distance of 6 Metres in People With Multiple Sclerosis
A clinical trial update evaluating the validity and reliability of a six-minute walk test performed over six metres in people with multiple …
-
CLINICAL_TRIALS research · 2026-02-04Clinical Trial Update: Retinal Imaging in Neurodegenerative Disease
This clinical trial update notes a Duke University-sponsored study evaluating retinal imaging as a biomarker across multiple neurodegenerati…
-
CLINICAL_TRIALS trial_result · 2026-02-04Clinical Trial Update: Oral Cladribine B-cell Study
The clinical trial update reports completed results for an oral cladribine B-cell study in multiple sclerosis, with results posted on 2026-0…
-
EMA approval · 2026-02-03EMA Authorised: Gilenya (fingolimod hydrochloride) — Novartis Europharm Limited
The European Medicines Agency authorised Gilenya (fingolimod hydrochloride) for the treatment of multiple sclerosis, with Novartis Europharm…